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Abstract
Background: Different Insulin-like Growth Factor Binding Proteins (IGFBPs) have been investigated as
potential biomarkers in several types of tumors. In this study, we examined both IGFBP-3 and -4 levels in
tissues and sera of melanoma patients representing different stages of melanoma progression.
Methods: The study cohort consisted of 132 melanoma patients (primary, n = 72; metastatic, n = 60; 64
Male, 68 Female; Median Age = 56) prospectively enrolled in the New York University School of Medicine
Interdisciplinary Melanoma Cooperative Group (NYU IMCG) between August 2002 and December 2006.
We assessed tumor-expression and circulating sera levels of IGFBP-3 and -4 using immunohistochemistry
and ELISA assays. Correlations with clinicopathologic parameters were examined using Wilcoxon rank-
sum tests and Spearman-rank correlation coefficients.
Results: Median IGFBP-4 tumor expression was significantly greater in primary versus metastatic patients
(70% versus 10%, p = 0.01) A trend for greater median IGFBP-3 sera concentration was observed in
metastatic versus primary patients (4.9 μg/ml vs. 3.4 μg/ml, respectively, p = 0.09). However, sera levels
fell within a normal range for IGFBP-3. Neither IGFBP-3 nor -4 correlated with survival in this subset of
patients.
Conclusion: Decreased IGFBP-4 tumor expression might be a step in the progression from primary to
metastatic melanoma. Our data lend support to a recently-described novel tumor suppressor role of
secreting IGFBPs in melanoma. However, data do not support the clinical utility of measuring levels of
IGFBP-3 and -4 in sera of melanoma patients.
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Current therapeutic strategies focus on targeted drug
development against pathways implicated in tumor signal
transduction, cell cycle regulation, or immune response
modulation. The insulin-like growth factor (IGF) axis is
one such system which contributes to human malignancy,
with overexpression of IGF1 receptor (IGF1R) noted in
several cancers, including melanoma. The IGF system
mediates signaling through a number of downstream
pathways, including the RAS-RAF-mitogen-activated pro-
tein kinase (MAPK) and phosphatidylinositol 3-kinase
(PI3K/AKT) pathways, with implications on the growth,
proliferation, and survival of both normal and malignant
cells. [1-3] Components of this system include the ligands
IGF1 and IGF2, their cell surface tyrosine kinase receptors
IGF1R and IGF2R, and seven IGF binding proteins
(IGFBP).
IGF1R has been shown to play a role in a number of
malignancies including melanoma, breast, prostate, and
lung. [4-6] Therapeutic approaches which disrupt IGF1R
signaling have been recently pursued, including receptor
blockade through antisense oligonucleotides, mono-
clonal antibodies, or tyrosine kinase inhibitors. Several of
these drugs are currently in Phase I trials as single agents
or in combination with chemotherapy. [7-11] A critical
aspect in the design of these trials has been the selection
of appropriate surrogate end-points of treatment
response. In addition to measuring objective tumor
response, a few studies have incorporated serum measure-
ment of IGFBP-3 as a biomarker of disease progression.
[12-16] IGFBP-3, the most abundant IGFBP in circulation,
is expressed in several cancers and was recently shown to
exert IGF-independent inhibitory activity on angiogenesis
in vivo.[17,18] IGFBP-3 has also been shown to be a p53-
response gene that induces apoptosis in an IGF-independ-
ent manner. [19] Furthermore, recent data indicate
IGFBP-3 may represent a potential node of cross-talk
between DNA-damage and TGF-B1-dependent signaling
pathways as it regulates several biomarkers of senescence
[20]. Finally, combination therapy with retinoid X recep-
tor-alpha ligands has led to synergistic induction of apop-
tosis in prostate cancer xenograft models.[21]
Few studies have reported on the expression of IGFBPs in
melanoma.[22,23] DNA microarray analysis data have
shown that IGFBP-3 expression is increased in metastases
relative to primary tumors, with siRNA gene knockdown
of IGFBP-3 in melanoma cells resulting in a reduction in
cell motility, migration, and invasion.[23] Although these
data support the role of IGFBP-3 as a potential biomarker
in melanoma, serum concentrations were not measured,
nor were clinicopathologic correlations or survival data
presented.[23] In melanoma, IGFBP-7 has been shown to
attenuate MAPK signaling, resulting in cellular senescence
in BRAF mutant melanocytes and apoptosis in BRAF
mutant melanoma cells, and data further suggest that it
possesses potential tumor-suppressor activity.[24] IGFBP-
4, the only member of the IGFBP family consistently
shown to inhibit IGF activity, has also been examined for
its role in cancer progression. Initial studies of IGFBP-4
gene therapy administered in colorectal cancer xenograft
models resulted in a decrease in tumor micro-vessel
counts and an increase in apoptosis.[25] Most recently,
Zhu et al. have shown that IGFBP-4 has IGF-independent
activity as a cardiogenic growth factor, and data suggest
that it acts as a competitive inhibitor of the canonical Wnt
signaling pathway [26]. IGFBP-4 levels may thus impact
tumor angiogenesis and progression in colon cancer in
vivo. To our knowledge, expression of IGFBP-4 in
melanoma has not been previously reported.
In this study, we have assessed the clinicopathologic rele-
vance of circulating as well as tumor-specific levels of
IGFBP-3 and -4 in melanoma and aimed to define the
most clinically relevant test to be integrated in correlative
studies of clinical trials targeting IGF.
Methods
Study Population
The study cohort consisted of 132 melanoma patients
(primary, n = 72; metastatic, n = 60; 64 Male, 68 Female;
Median Age = 56) prospectively enrolled in the NYU
IMCG between August 2002 and December 2006. Clin-
icopathologic, demographic, and survival data were
recorded prospectively for all patients. The NYU Institu-
tional Review Board approved this study and informed
consent was obtained from all patients at the time of
enrollment.
Immunohistochemistry
IGFBP-3 protein expression was assessed by immunohis-
tochemistry in formalin-fixed, paraffin embedded tissue
specimens from 96 patients using mouse anti-human
IGFBP-3 antibody (R&D Systems Minneapolis, MN),
including 59 specimens from primary patients and 37
specimens from patients with metastatic disease. Simi-
larly, formalin-fixed, paraffin embedded tissue specimens
from 123 patients were examined using goat anti-human
IGFBP-4 antibody (R&D Systems), including 66 speci-
mens from primary patients, and 57 specimens from
patients with metastatic disease. In brief, sections were
deparaffinized in xylene (3 changes), rehydrated through
graded alcohols (3 changes 100% ethanol, 3 changes 95%
ethanol), and rinsed in distilled water. Heat-induced
epitope retrieval was performed in 10 mM citrate buffer
pH 6.0 in a 1200-Watt microwave oven at 90% power.
IGFBP-4 was retrieved for 10 minutes and IGFBP-3 for 20
minutes, respectively. Sections were allowed to cool for 30
minutes and then rinsed in distilled water. Antibody incu-Page 2 of 9
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NEXes instrument (Ventana Medical Systems Tucson, Ari-
zona) using Ventana's reagent buffer and detection kits,
unless otherwise noted. Endogenous peroxidase activity
was blocked with hydrogen peroxide. IGFBP-3 was
diluted 1:50 and IGFBP-4 was diluted 1:25 and incubated
overnight at room temperature. IGFBP-3 was detected by
the application of a biotinylated goat anti-mouse (Ven-
tana Medical Systems). IGFBP-4 was detected was
detected using a biotinylated horse anti-goat (Vector Lab-
oratories Burlingame, California) diluted 1:200 and incu-
bated for 30 minutes. Both were followed by the
application of streptavidin-horseradish-peroxidase conju-
gate. The complex was visualized with 3,3 diaminobenzi-
dene and enhanced with copper sulfate. Slides were
washed in distilled water, counterstained with hematoxy-
lin, dehydrated and mounted with permanent media.
Appropriate positive and negative controls were included
with the study sections.
The expression of IGFBP-3 and -4 were scored by an
attending pathologist (H.Y.), who was blinded to the
patients' clinical data. Both IGFBP-3 and -4 protein
expression were calculated based on the percentage of
tumor cells which exhibited positive cytoplasmic staining.
Immunoreactivity was assessed on a continuous scale
with values ranging from undetectable levels (0%) to
homogenous staining (100%) of invasive melanoma
cells.
Measuring IGFBP-3 and IGFBP-4 using ELISA
Serum specimens from 82 patients were collected and
analyzed for IGFBP-3 (40 primary, 42 metastatic). IGFBP-
4 expression was examined by ELISA assay in 80 of the 82
patients as the IGFBP-3 ELISA assay exhausted 2 patient
sera samples. All serum samples were collected in 10 ml
BD serum tubes, stored immediately at 4°C, and then cen-
trifuged at 10°C for 10 minutes at 1,500–2,000 ×g. The
supernatant serum was then aliquoted into 1.5 ml cryovi-
als and stored at -80°C until further use.
Two commercially-available IGFBP-3 and -4 two-step
sandwich ELISA assays were used to quantify the respec-
tive serum concentrations of these proteins (DSL-10-7300
Active IGFBP-3 ELISA and DSL-10-7300 Active IGFBP-4
ELISA, Diagnostic Systems Laboratories, Inc., Webster,
TX). A 96-well flat bottom microtiter plate was coated
with either mouse anti-human IGFBP-3 antibody or goat
anti-IGFBP-4 antibody, respectively, and incubated for 1
hour at room temperature shaking at fast speed (500–700
rpm) on an orbital microplate shaker. After several washes
with buffered saline containing a nonionic detergent
(Wash Buffer), plates were incubated with either the anti-
IGFBP-3 or the anti-IGFBP-4 antibody conjugated to the
enzyme horseradish peroxidase in a protein-based (BSA)
buffer with a non-mercury preservative (Antibody-
Enzyme Conjugate Solution) for 30 minutes at room tem-
perature while shaking at a fast speed (500–700 rpm).
After three additional washes with Wash Buffer, 3,3',5,5'-
tetramethylbenzidine in citrate buffer with hydrogen per-
oxide (TMB Chromogen Solution) was added to each well
and incubated while shaking at room temperature for 10
minutes. The reaction was stopped with a (Stopping Solu-
tion) and the absorbance of the solution in the wells was
read using a microplate reader set to 450 nm, and known
concentrations of IGFBP-3 or -4 standards were utilized to
establish a standard curve to extrapolate IGFBP-3 or -4
concentration within patient samples (DSL-10-7300
Active IGFBP-3 ELISA and DSL-10-7300 Active IGFBP-4
ELISA, Diagnostic Systems Laboratories, Inc., Webster,
TX). Standards for IGFBP-3 were: Standard A, containing
0 ng/ml IGFBP-3 in a non-human serum with a non-mer-
cury preservative, and IGFBP-3 Standard B-F, containing
concentrations of respectively 5, 20, 40, 125, and 250 ng/
ml IGFBP-3 in a non-human serum with a non-mercury
preservative. The IGFBP-3 controls were two samples con-
taining low and high concentrations of rhIGFBP-3 in a
protein-based BSA buffer with a non-mercury preservative
(10–6651 and 10–6652, Diagnostic Systems Laborato-
ries, Inc., Webster, TX). Similarly, corresponding stand-
ards and controls for IGFBP-4 were used.
Statistical Analysis
Baseline demographic and clinicopathologic characteris-
tics were calculated for the study cohort. Associations
between IGFBP-3 and -4 expression and age, gender,
tumor thickness, histopathologic subtype, and metastatic
tumor type were evaluated by the t-test (or Wilcoxon rank-
sum test), the analysis of variance (ANOVA) test (or
Kruskal-Wallis test), and the Spearman-rank correlation
coefficient, as appropriate. For the analysis of histopatho-
logic subtype, patients were collectively grouped into
those who were diagnosed with superficial spreading
melanoma, or "other" subtypes. To analyze mean and
median IGFBP-3 and -4 tumor expression and sera con-
centrations, patients were grouped into those with pri-
mary disease and those with metastatic disease. The
relationship between IGFBP-3 and -4 expression and
patient overall survival was assessed with a hazard ratio
derived from a Cox proportional hazards regression
model. Overall survival was computed as the difference
between the date of last follow-up and the date of initial
diagnosis. Spearman correlation coefficients were used to
examine the relationship between IGFBP-3 and -4 expres-
sions in tissue specimens and concentration in sera. Sera
data were represented by box and whisker plots, with
upper and lower limits of the boxes indicating the 75th
and 25th percentiles, respectively, and the central, hori-
zontal line representing the median. Outliers are values
that are more than 1.5 times the inter-quartile distancePage 3 of 9
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cated by points outside of the box and whiskers. 39
patients had both sera and tumor specimens available for
correlation of IGFBP-3 expression and 56 patients had
both sera and tumor specimens available for IGFBP-4 cor-
relation. All P values are two-sided with statistical signifi-
cance evaluated at the 0.05 alpha level. All analyses were
performed in SAS version 9.1 (SAS Institute, Inc., Cary,
NC) and Stata version 8.0 (Stata Corporation, College Sta-
tion, TX).
Results
IGFBP-3 and IGFBP-4 expression in primary melanomas
We examined the expression of IGFBP-3 and -4 in primary
melanomas from 72 primary patients, according to 6th
Edition of the AJCC staging guidelines (Table 1). The
median Breslow thickness for primary tumors was 0.45
mm, 40 tumors were axial, and 32 were located on the
extremities. Histological examination revealed 68 superfi-
cial spreading type melanomas, and the remainder were
nodular (n = 2) and lentigo maligna (n = 2) melanomas.
Both IGFBP-3 and -4 exhibited cytoplasmic localization,
but IGFBP-4 staining was more granular (Figure 1A and
1B). Median IGFBP-3 expression in primary melanoma
tumor specimens was 80%, while median IGFBP-4 expres-
sion in primary tumors was 70%. Clinicopathologic cor-
relation with IGFBP-3 and -4 expressions in primary
melanoma samples revealed no significant association
between IGFBP-3 or -4 tissue expression, or tumor thick-
ness.
IGFBP-3 and IGFBP-4 expression in metastatic melanomas
We examined the expression of IGFBP-3 and -4 in 60
melanoma tumors from 60 patients with metastatic dis-
ease according to 6th Edition of the AJCC staging guide-
lines (Table 2). Again, both IGFBP-3 and -4 exhibited
cytoplasmic localization (Figure 2A and 2B). The median
IGFBP-3 expression in metastatic melanoma specimens
was 90%, slightly higher than its expression in primary
tumors. The median IGFBP-4 expression in metastatic
melanoma specimens was 10%, significantly lower than
IGFBP-4 expression in primary tumors (p = 0.01, Wil-
coxon rank-sum test). Clinicopathologic correlation with
IGFBP-3 and -4 expressions in metastatic melanoma sam-
ples revealed no significant association between IGFBP-3
or -4 expression and gender, regional versus distant dis-
ease, and presence of multiple metastases. While neither
IGFBP-3 or -4 tissue or sera expression had any significant
correlation with overall survival, we did observe a trend
towards shorter median survival in patients with elevated
IGFBP-4 tissue expression (mean = 32.7%) compared to
those with lower IGFBP-4 expression (mean 24.9%, p =
0.07).
Association between IGFBP-3 expression in tissue and sera
Of the 82 sera samples analyzed by the IGFBP-3 ELISA
assay, 20 were eliminated from analysis due to hemolysis
and of the 62 remaining samples, 27 were from primary
patients and 35 were from metastatic patients. A trend for
greater median IGFBP-3 sera concentration was observed
in metastatic versus primary patients (4.9 ug/ml vs. 3.4
ug/ml, respectively, p = 0.26, Wilcoxon rank-sum test, Fig-
ure 3A). Data regarding both tissue and sera IGFBP-3
expression was available for 39 patients. No correlation
IGFBP-3 and -4 expressions in primary melanoma tissue were evaluated with IHCFigure 1
IGFBP-3 and -4 expressions in primary melanoma tissue were evaluated with IHC. (A) IGFBP-3 protein had low 
levels of expression in primary melanoma tissues, while (B) IGFBP-4 protein had high levels of expression in primary melanoma 
tissue. All images are at 20× magnification.Page 4 of 9
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sue expression (p = 0.25). IGFBP-3 sera concentration did
not correlate significantly with gender, age, thickness, ana-
tomic location, regional versus distant disease, or pres-
ence of multiple metastases (data not shown).
Association between IGFBP-4 expression in tissue and sera
IGFBP-4 expression was examined by ELISA assay in 80 of
the 82 patients as the IGFBP-3 ELISA assay exhausted 2
patient sera samples. Of the 80 samples, 20 were elimi-
nated from analysis due to hemolysis observed in those
aliquots. IGFBP-4 serum levels were quantified in 60 via-
ble samples (26 primary, 34 metastatic), and no signifi-
cant difference was observed between the median IGFBP-
4 concentration in primary patients versus metastatic
patients (37.2 ng/μl vs. 41.42 ng/μl, respectively, p = 0.25,
Wilcoxon rank-sum test, Figure 3B). Data regarding both
tissue and sera IGFBP-4 expression was available for 56
patients. Analyses revealed no association between the
expression of IGFBP-4 in tissue and its concentration in
sera (p = 0.57). There was no association between IGFBP-
4 sera concentration and gender, thickness, anatomic
location, regional versus distant disease, and presence of
multiple metastases.
Discussion
Our study documents several important observations.
First, we demonstrate that tissue expression of IGFBP-4
decreases in the progression from primary to metastatic
melanoma. Furthermore, we did not detect a correlation
between sera concentration and tissue expression for
either IGFBP-3 or -4. These data suggest that IGFBPs local-
ized to the tumor compartment may be differentially reg-
ulated compared to circulating IGFBPs. We also show that
tissue expression of IGFBP-3 and -4 may be more clini-
cally relevant than circulating levels, results which could
reflect their systemic proteolytic cleavage and physiologic
regulation by other endocrine hormones. While our study
did not use semiquantitative analysis to score the immu-
noreactivity of the specimens, future studies incorporating
this analysis will generate immunoreactivity data that may
more closely reflect relative gene product expression levels
in tissue. Thus, it is possible that mechanisms by which
Table 1: Primary Patients Baseline Characteristics (n = 72)
Variables n(%)
Age (y)









Mean (± SD) 0.50 ± 0.25
Median 0.45
Histologic Type
Superficial Spreading 68 (94.4)
Nodular 2 (2.78)




IGFBP-3 and -4 expressions in metastatic melanoma tissue were evaluated with IHCFigure 2
IGFBP-3 and -4 expressions in metastatic melanoma tissue were evaluated with IHC. (A) IGFBP-3 protein had 
high levels of expression in metastatic melanoma tissue. (B) IGFBP-4 low levels of expression in metastatic melanoma tissue. All 
images are at 20× magnification.Page 5 of 9
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tumor microenvironment and plasma, leading to
increases in tumor expression without concurrent
increases in circulatory levels, or vice versa.
We report for the first time data which demonstrate the
up-regulation of IGFBP-4 expression in primary versus
metastatic melanoma specimens, and these data suggest
that IGFBP-4 may function as a tumor suppressor. This is
consistent with its biologic function as an inhibitor of IGF
activity.[27] While previous studies investigating the over-
expression of IGFBP-4 in both colorectal and prostate can-
cers in vivo found evidence of decreased tumor
proliferation, these correlations have not yet been per-
formed in melanoma.[25,28] In this regard, our group has
found evidence to suggest that integrin αvβ3 can mediate
the expression of IGFBP-4 Specifically, treatment of M21
melanoma cells with a monoclonal antibody directed
against αvβ3 results in an elevation of IGFBP-4 levels both
in vitro and in vivo. Furthermore, immunohistochemistry
data from 132 melanoma patient tumor specimens (pri-
mary, n = 72; metastatic, n = 63) demonstrate that in the
progression from primary to metastatic melanoma,
IGFBP-4 expression decreases while integrin avb3 expres-
sion increases (data not shown). These findings further
support the potential role of IGFBP-4 as an endogenous
inhibitor of angiogenesis and tumor growth in
melanoma.
IGFBPs have been shown to have IGF-independent activi-
ties in multiple cellular pathways. [19,20,26] Wajapeyee
et al recently described a novel function of IGFBPs in
BRAF-mediated cellular senescence.[24] Specifically, data
suggest that IGFBP-7 acts through a negative feedback
loop to attenuate MAPK signaling, resulting in cellular
senescence in BRAF mutant melanocytes and apoptosis in
BRAF mutant melanoma cells. Furthermore, they found a
high level of IGFBP-7 expression in BRAF mutant nevi and
undetectable levels in BRAF mutant melanomas, suggest-
ing that this protein may act as a tumor-suppressor in
melanoma. Although IGFBP-3 and -4 have not been
examined in this context, it is possible that other IGFBPs
have implications on BRAF signaling and could poten-
tially serve as surrogate markers for BRAF positivity. Fur-
ther examination of IGFBPs in relation to MAPK signaling
and BRAF mutation status are thus warranted.
Our data on IGFBP-3 expression in melanoma do not
strongly support a previously published report which
found up-regulation of IGFBP-3 in melanoma metastases
compared to primary melanoma specimens.[23] Our data
indicates only a slight difference in IGFBP-3 expression
between metastatic and primary tumors, and there was no
significant difference in IGFBP-3 sera levels between met-
astatic and primary patients. In fact, IGFBP-3 sera levels of
the majority of the melanoma patients fell within the nor-
mal expected range for adults. Interestingly, these data
also contrast with what has been recently presented in
prostate cancer. In those studies, IGFBP-3 was shown to
exert direct, tumor-suppressive effects via IGF-independ-
ent inhibition of angiogenesis[18] and both IGF-depend-
ent and -independent induction of apoptosis. [29-31]
Thus, it appears that IGFBP-3 plays different roles among
different cancers.
The prognostic relevance of IGFBP-3 or -4 expressions in
melanoma also requires further investigation. It has been
previously reported that low tumor expression of IGFBP-
3 in patients with primary hepatocellular carcinoma was
independently associated with poor survival.[32] Consist-
ent with these data, high plasma levels of IGFBP-3 were
shown to be predictive of longer progression-free survival
in patients with advanced non-small cell lung cancer.[33]
However, to our knowledge, no reports exist on the prog-
nostic relevance of IGFBP-3 or -4 expressions in
melanoma.
Our data do not support the further development of
IGFBPs as surrogate endpoint biomarkers for treatments
targeting IGF1R. Although sera shedding of IGFBP-3
increased slightly in the progression from primary to met-
astatic melanoma, the majority of IGFBP-3 sera levels in
the melanoma patient cohort fell within the expected
range for healthy adults (1.5–5.6 ug/ml). Standard IGFBP-
4 sera levels have yet to be established for comparison
(Diagnostic Systems Laboratories, Inc.). Interestingly,
nearly 30% of patients studied (10 primary, 15 metastatic
patients) had IGFBP-3 sera concentrations up to twice the
expected normal maximum, and 5 of the 15 metastatic
Table 2: Metastatic Patients Baseline Characteristics (n = 60)
Variables n(%)
Age (y)












Regional Skin/Subcutaneous 20 (33.3)
Regional Lymph Node 26 (43.3)
Distant Lymph Node 2 (3.33)
Distant Skin/Subcutaneous 6 (10.0)
Visceral 6 (10.0)Page 6 of 9
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IGFBP-3 and -4 sera concentration for primary and metastatic patientsFigure 3
IGFBP-3 and -4 sera concentration for primary and metastatic patients. A. Median IGFBP-3 in sera of primary 
patients was 3.4 μg/ml compared with 4.9 μg/ml, in metastatic patients (p = 0.08 by Wilcoxon rank-sum test). B. Median 
IGFBP-4 in sera of primary patients was 37.2 ng/ml compared with 41.2 ng/ml, in metastatic patients (p = 0.25 by Wilcoxon 
rank-sum test). The boxes represent the inter-quartile distances with upper and lower limits of the boxes indicating the 75th 
and 25th percentiles, respectively, and the central, horizontal line representing the median. Outliers are values that are more 
than 1.5 times the inter-quartile distance above the 75th or below the 25th percentile and are indicated by points outside of the 
box and whiskers.
Journal of Translational Medicine 2008, 6:70 http://www.translational-medicine.com/content/6/1/70patients with high serum IGFBP-3 died of melanoma less
than 2 years after the date of blood collection. While in
principle, taking multiple sera collection points may be
more informative, this is an observation made from a
small subset of the patients studied. Data from the study
at large indicate that the majority of patients' IGFBP-3 sera
levels fell within the expected normal range for adults.
Furthermore, it is known that circulating levels of IGFBP-
3 and -4 can be affected by multiple, systemic confound-
ing factors, including diet, exercise, pregnancy, growth
hormone, and age.[34,35] Therefore, multiple collections
will not change the overall conclusion that there is no sig-
nificant difference in sera levels of either IGFBP-3 or -4
between primary and metastatic melanoma patients.
Conclusion
These data indicate that decreased IGFBP-4 tumor expres-
sion might be a step in the progression from primary to
metastatic melanoma. Furthermore, our data lend sup-
port to a recently-described novel tumor suppressor role
of secreting IGFBPs in melanoma. However, data do not
support the clinical utility of measuring levels of IGFBP-3
and -4 in sera of melanoma patients.
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